RaySearch Laboratories AB (publ)
RSLBF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $332 | $305 | $332 | $323 |
| % Growth | 9% | -8.1% | 2.8% | – |
| Cost of Goods Sold | $12 | $28 | $26 | $25 |
| Gross Profit | $321 | $277 | $305 | $298 |
| % Margin | 96.4% | 90.8% | 92% | 92.3% |
| R&D Expenses | $68 | $73 | $59 | $71 |
| G&A Expenses | $73 | $72 | $68 | $72 |
| SG&A Expenses | $164 | $162 | $157 | $164 |
| Sales & Mktg Exp. | $91 | $90 | $89 | $91 |
| Other Operating Expenses | -$1 | $6 | $15 | -$11 |
| Operating Expenses | $231 | $241 | $230 | $224 |
| Operating Income | $89 | $36 | $75 | $74 |
| % Margin | 26.8% | 11.9% | 22.6% | 22.8% |
| Other Income/Exp. Net | -$1 | $3 | -$4 | $4 |
| Pre-Tax Income | $89 | $40 | $71 | $77 |
| Tax Expense | $17 | $9 | $14 | $17 |
| Net Income | $72 | $31 | $57 | $60 |
| % Margin | 21.5% | 10.1% | 17.1% | 18.6% |
| EPS | 2.09 | 0.9 | 1.66 | 1.75 |
| % Growth | 132.2% | -45.8% | -5.1% | – |
| EPS Diluted | 2.09 | 0.9 | 1.66 | 1.75 |
| Weighted Avg Shares Out | 34 | 34 | 34 | 34 |
| Weighted Avg Shares Out Dil | 34 | 34 | 34 | 34 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $3 | $0 | $4 |
| Interest Expense | $0 | $0 | $4 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $89 | $36 | $75 | $74 |
| % Margin | 26.8% | 11.9% | 22.6% | 22.8% |